. Author manuscript; available in PMC: 2009 Jul 6.

Published in final edited form as: Virology. 2007 Dec 26;373(1):72–84. doi: 10.1016/j.virol.2007.11.005

Table 1.

Immunogenicity with selected immunogens and elicite neutralization activity against selected pseudotyped HIV-1 isolates^a

Group	Immunogen^b	Immunogen	Rabbits	HXBc2		SF162		MN		MW965

	Prime Wk 0, 4	Boost Wk 8, 12	IDs	Post 2	Post 4	Post 2	Post 4	Post 2	Post 4	Post 2	Post 4

				IC₅₀
I	Blank beads^c	Blank beads	1	<5	<5	<5	<5	<5	<5	<5	<5
			2	<5	<5	<5	<5	<5	<5	<5	<5
II	HBsAg particles	HBsAg particles	3	<5	<5	<5	<5	<5	<5	<5	<5
			4	<5	<5	<5	<5	<5	<5	<5	<5
III	HBsAg particles	ADA Env-PLs	5	<5	<5	<5	<5	<5	<5	<5	<5
			6	<5	<5	<5	<5	<5	<5	<5	<5
IV	HBsAg MPER particles	HBsAg MEPR particles	7	<5	<5	<5	<5	<5	<5	<5	<5
			8	<5	<5	<5	<5	<5	<5	<5	<5
			9	<5	<5	<5	<5	<5	<5	<5	<5
			10	<5	<5	<5	<5	<5	<5	<5	<5
V	HBsAg MPER particles	ADA Env-PLs	11	<5	<5	<5	<5	<5	<5	<5	49
			12	<5	<5	<5	35	<5	1428	<5	449
			13	<5	<5	<5	<5	<5	6	<5	16
			14	<5	<5	<5	<5	<5	<5	<5	45
VI	ADA Evn-PLs	HBsAg MPER particles	15	<5	<5	<5	<5	<5	20	<5	<5
			16	<5	<5	<5	<5	<5	<5	13	<5
			17	<5	<5	<5	<5	<5	<5	<5	<5
			18	<5	<5	<5	<5	<5	<5	<5	<5
VII	ADA Env-PLs	HBsAg particles	19	<5	<5	16	<5	<5	<5	112	<5
			20	<5	<5	30	<5	<5	<5	166	154
VIII	ADA Env-PLs	ADA Env-PLs	21	<5	11	<5	18	<5	3310	<5	345
			22	<5	<5	<5	<5	<5	9	100	269
			23	<5	<5	18	432	<5	4107	99	886
			24	<5	<5	<5	<5	<5	3597	<5	346
			25	<5	<5	<5	58	1631	1809	74	841
			26	116	1485	418	513	520	818	258	470
IX	HBsAg MPER-20 particle	ADA Env-PLs	27	<5	<5	<5	<5	<5	391	<5	137
			28	<5	<5	<5	<5	<5	<5	<5	<5
			29	<5	<5	<5	59	<5	30821	<5	85
			30	<5	<5	<5	<5	<5	<5	<5	28
X	HBsAg MPR-20 particles	HBsAg MPER-20 particles	31	<5	<5	<5	<5	<5	<5	<5	<5
			32	<5	<5	<5	<5	<5	<5	<5	<5
			33	<5	<5	<5	<5	<5	<5	<5	<5
			34	<5	<5	<5	<5	<5	<5	<5	<5
			35	<5	<5	<5	<5	<5	<5	<5	<5
			36	<5	<5	<5	<5	<5	<5	<5	<5

Shown are neutralization titers from a single-round neutralization assay with sera after the second and fourth inoculations against the indicated isolates. The values represent reciprocal serum dilutions to achieve 50 % (IC₅₀) neutralization.

All immunogens were combined with CpG+Alum as described in the Methods.

The immunogens of blank beads and unmodified Hepatitis B surface antigen particles (HBsAg) were used a negative controls for either prime or boost as indicated.